FOI 5694-Patients treated with certain drugs

Date: 25 September 2019 to 25 September 2022

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the following conditions.

 

Treatment

Total

Rheumatoid Arthritis

Ankylosing Spondylitis

Psoriatic Arthritis

Psoriasis

Crohns disease

Ulcerative Colitis

Abatacept (Orencia)

 

 

 

Adalimumab biosimilar [Amgevita]

 

 

 

Adalimumab biosimilar [Hulio]

 

 

 

Adalimumab [Humira]

 

 

 

Adalimumab biosimilar [Hyrimoz]

 

 

 

Adalimumab biosimilar [Imraldi]

 

 

 

Apremilast (Otezla)

 

 

 

Baricitinib (Olumiant)

 

 

 

Brodalumab (Kyntheum)

 

 

 

Certolizumab (Cimzia)

 

 

 

Dimethyl Fumarate (Skilarence)

 

 

 

Etanercept (Enbrel)

 

 

 

Etanercept Biosimilar (Benepali)

 

 

 

Etanercept Biosimilar (Erelzi)

 

 

 

Golimumab (Simponi)

 

 

 

Guselkumab (Tremfya)

 

 

 

Infliximab [Flixabi]

 

 

 

Infliximab [Inflectra]

 

 

 

Infliximab [Remicade]

 

 

 

Infliximab [Remsima]

 

 

 

Ixekizumab (Taltz)

 

 

 

Rituximab (Mabthera)

 

 

 

Rituximab Biosimilar (Rixathon)

 

 

 

Rituximab Biosimilar (Truxima)

 

 

 

Sarilumab (Kevzara)

 

 

 

Secukinumab (Cosentyx)

 

 

 

Tildrakizumab (Ilumetri)

 

 

 

Tocilizumab (Ro Actemra)

 

 

 

Tofacitinib (Xeljanz)

 

 

 

Ustekinumab (Stelara)

 

 

 

Vedolizumab (Entyvio)

 

 

 

 

  • Request ID:
    FOI 5694
  • Category:
    Clinical - Drugs
  • Response:

    Response attached